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Abstract
Background: It has been estimated that between 5% and 10% of women diagnosed with breast cancer have
a hereditary form of the disease, primarily caused by a BRCA1 or BRCA2 gene mutation. Such women have an
increased risk of developing a new primary breast and/or ovarian tumor, and may therefore opt for
preventive surgery (e.g., bilateral mastectomy, oophorectomy). It is common practice to offer high-risk
patients genetic counseling and DNA testing after their primary treatment, with genetic test results being
available within 4-6 months. However, some non-commercial laboratories can currently generate test results
within 3 to 6 weeks, and thus make it possible to provide rapid genetic counseling and testing (RGCT) prior
to primary treatment. The aim of this study is to determine the effect of RGCT on treatment decisions and
on psychosocial health.
Methods/Design: In this randomized controlled trial, 255 newly diagnosed breast cancer patients with at least a
10% risk of carrying a BRCA gene mutation are being recruited from 12 hospitals in the Netherlands. Participants
are randomized in a 2:1 ratio to either a RGCT intervention group (the offer of RGCT directly following diagnosis
with tests results available before surgical treatment) or to a usual care control group. The primary behavioral
outcome is the uptake of direct bilateral mastectomy or delayed prophylactic contralateral mastectomy.
Psychosocial outcomes include cancer risk perception, cancer-related worry and distress, health-related quality of
life, decisional satisfaction and the perceived need for and use of additional decisional counseling and psychosocial
support. Data are collected via medical chart audits and self-report questionnaires administered prior to
randomization, and at 6 month and at 12 month follow-up.
Discussion: This trial will provide essential information on the impact of RGCT on the choice of primary surgical
treatment among women with breast cancer with an increased risk of hereditary cancer. This study will also
provide data on the psychosocial consequences of RGCT and of risk-reducing behavior.
Trial registration: The study is registered at the Netherlands Trial Register (NTR1493) and ClinicalTrials.gov
(NCT00783822).
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Breast cancer and genetics
Breast cancer is the most frequently occurring malig-
nancy in women in the Netherlands. Approximately 1 in
8 women will develop the disease during their lifetime,
resulting in approximately 12,000 new cases annually. A
positive family history of breast cancer is the single
strongest risk factor for developing the disease. In
5%-10% of the cases, breast cancer has a hereditary
basis. In 15%-30% of patients from high-risk families,
breast cancer is caused by a germline mutation in the
BRCA1 or BRCA2 gene [1-4]. A similar percentage of
breast cancers is expected to have a genetic basis due to
mutations in (combinations of) other low penetrance
breast cancer susceptibility genes [5]. Current estimates
indicate that women who carry mutations in the BRCA1
or BRCA2 genes have up to an 85% lifetime risk of
developing breast cancer, and can also have up to a 60%
lifetime risk of developing ovarian cancer [6,7]. Breast
cancer patients who carry a BRCA1/2 mutation have a
3% annual risk of developing contralateral breast cancer,
with the overall risk being as high as 52% by the age of
70 [7,8]. For BRCA1/2 carriers who were diagnosed with
breast cancer before the age of 40 years, the cumulative
risk of developing contralateral breast cancer after a fol-
low up of 25 years is even higher, i.e. 63% [9]. Given
these high rates of new primary cancers, breast cancer
patients with strong family histories of the disease may
b e n e f i tf r o mg e n e t i cc o u n s e l i n ga n dt e s t i n ga sam e a n s
of making a well-informed decision on preventive
measures.
Genetic counseling and testing in breast cancer patients
The objectives of cancer genetic counseling, in gen-
eral, are to improve knowledge and understanding of
the possible genetic basis of the disease, of personal
risks of developing cancer, and of the possible conse-
quences of undergoing genetic testing [10,11]. In the
case of breast cancer, the goal of genetic counseling is
to ensure that women have been sufficiently educated
regarding inherited breast/ovarian cancer to make
informed decisions concerning genetic testing, and
available preventive and treatment options [12,13].
The majority of published studies have found that
genetic counseling is effective in increasing knowledge
and awareness of cancer risk, and of the consequences
of genetic testing [11,14-16]. Factors that may be indi-
cative of hereditary breast cancer are young age at
diagnosis, multiple family members with breast cancer,
male relatives with breast cancer, breast and ovarian
cancer in the family and/or breast cancer and prostate
cancer in family members at a relatively young age.
Women with one or more of these factors are consid-
ered to have a 10% risk or greater of carrying a BRCA1
or BRCA2 gene mutation, and are thus, in general,
considered as candidates for DNA testing. Genetic
counseling and DNA testing for breast cancer usually
takes approximately 4-6 months to complete. How-
ever, some hospitals and non-commercial laboratories
are now able to generate test results within 3 to 6
weeks. This technology of rapid genetic testing creates
new opportunities for providing both women and
their treating surgeons with information potentially
relevant for deciding between available treatment
options, including type of surgery and adjuvant ther-
apy [17-19].
Newly diagnosed patients who learn that they are
gene mutation carriers may decide to undergo a mas-
tectomy rather than a lumpectomy, or bilateral mastect-
omy (BLM) rather than unilateral mastectomy. Recent
studies have shown that BLM and delayed contralateral
prophylactic mastectomy (CPM) substantially reduce
the risk of contralateral breast cancer, while studies on
survival have yielded mixed results [20-23]. Additionally,
women who choose unilateral or bilateral mastectomy
as their initial surgical treatment will often be spared
the necessity of undergoing radiation therapy. However,
rapid genetic counseling and testing (RGCT) may neces-
sitate some delay in surgical treatment until DNA test
results are available. Previous studies have indicated
that the majority of newly diagnosed breast cancer
patients at high risk of being BRCA1/2 mutation car-
riers will accept the invitation to undergo RGCT, and
that the DNA test results can have a substantial impact
on the choice of surgery [3,24,25]. In these British and
American studies, between one-half and two-thirds of
the breast cancer patients carrying a BRCA1 or BRCA2
mutation opted for a bilateral mastectomy, with some
opting for a delayed CPM instead of direct BLM. Addi-
tionally, between 16% and 24% of high-risk patients
who test negative for a BRCA1/2 mutation opted for
BLM [3,25].
The psychosocial impact of genetic testing in
recently diagnosed breast cancer patients has been the
subject of only limited study [26]. Although disclosure
of test results may increase short term psychological
distress, there is no evidence to suggest that there is a
sustained increase in levels of distress as a result of
such counseling or testing [26-28]. A Dutch study
showed that an active approach to genetic counseling
in patients recently diagnosed with breast cancer and
in an early stage of primary treatment (i.e. 7-8 weeks
after surgery), did not increase psychological stress
significantly [27,28]. In addition, in a small pilot study
in 8 women who were offered RGCT following their
breast cancer diagnosis but prior to surgery, none
reported that the offer of RGCT had added signifi-
cantly to the stress that they were already experiencing
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also relatively little known about the psychological
impact of BLM or CPM. The few studies performed,
to date, all but one of which was retrospective in nat-
ure, have reported high levels of satisfaction with CPM
and no adverse effects on health-related quality of life
(HRQL) [30-32].
To summarize, recent advances in the technology of
genetic testing for breast cancer open the possibility of
offering women with a suspected hereditary form of the
disease the opportunity to undergo RGCT in the period
of time between receiving the diagnosis and undergoing
primary treatment. For those high-risk women who opt
for direct BLM or delayed CPM, there are clear advan-
tages in terms of reduction in the risk of contralateral
disease, although an improvement in survival has not
yet been convincingly demonstrated [20,22]. Women
who choose for (bilateral) mastectomy can also avoid
having to undergo radiotherapy. This, in turn, can
improve the results of breast reconstruction [33]. How-
ever, there are insufficient data available on the impact
of RGCT, when offered routinely to high-risk women,
on medical decision-making, and there is relatively little
known about the impact of RGCT on cancer-specific
distress, treatment satisfaction, and HRQL.
Objectives and research hypotheses
This study is evaluating the behavioral and psychosocial
effects of the routine offer of RGCT to newly diagnosed
primary breast cancer patients who meet criteria for
being at-risk of having a BRCA1 or BRCA2 gene muta-
tion. RGCT is being offered to women shortly after
diagnosis, prior to surgery. The comparison group is
composed of women who receive usual care (UC), in
which RGCT is available but is rarely recommended or
requested.
The specific research hypotheses are:
1. A significantly greater percentage of women in the
RGCT group as compared to the UC group will
undergo a direct bilateral mastectomy (BLM).
2. A significantly greater percentage of women in the
RGCT group as compared to the UC group will
undergo a delayed prophylactic contralateral mastect-
omy (CPM).
3. Women in the RGCT group will report significantly
lower levels of perceived cancer risk, cancer worries,
and cancer-related distress at 12 month follow-up than
women in the UC group.
4. Women in the RGCT will have significantly higher
levels of knowledge of genetic issues in breast cancer,
and higher levels of decisional satisfaction than women
in the UC group.
5. Following from hypotheses 1 and 2, women in the
RGCT group will report significantly more problems
with body image and sexuality than those in the UC
group. No significant differences will be observed
between the RGCT and the UC groups on other HRQL
outcomes.
Methods/Design
This is a multicenter, randomized, controlled trial in
which patients are randomized to RGCT or to UC on a
2:1 basis. The primary clinical outcomes include: the
uptake of direct BLM or of delayed CPM. Data on surgi-
cal outcomes will be abstracted from the medical records.
This protocol follows the CONSORT guidelines [34].
Psychosocial outcomes include: perceived risk for ipsi-
lateral and contralateral breast cancer and for ovarian
cancer, cancer-related worry and distress; knowledge of
genetic aspects of breast cancer; decisional satisfaction;
and HRQL. The study also is evaluating women’s
experience of and satisfaction with RGCT (i.e., the tim-
ing and quality of the services provided, the perceived
impact on treatment decisions, the perceived need for
additional psychosocial support, etc.), and the surgeons’
experience with RGCT. Standardized questionnaires are
administered at study entry (prior to randomization),
a n da t6m o n t ha n d1 2m o n t hf o l l o w - u p( s e ef i g u r e1 ) .
The institutional review boards of all participating hos-
pitals have approved the study. The study is registered
at the Netherlands Trial Register (NTR1493) and Clini-
calTrials.gov (NCT00783822).
Participants
The study sample will be composed of 255 women with
a clinically confirmed, newly diagnosed primary breast
cancer or ductal carcinoma in situ (DCIS) who meet at
least one of the criteria for referral for genetic counsel-
ing and DNA analysis according to the Dutch Institute
for Healthcare Improvement (CBO). These criteria are:
(1) age at time of breast cancer diagnosis less than 35
years; (2) previous history of cancer in the contralateral
breast, with the first breast cancer diagnosis at less than
50 years of age; (3) previous personal history of ovarian
cancer; (4) a family history of ovarian cancer; (5) a first
degree male relative with breast cancer; (6) breast cancer
diagnosed under the age of 50 years, with a first degree
relative diagnosed with breast cancer under the age of
50 years; (7) breast cancer diagnosed under the age of
50 years, with a relative with prostate cancer diagnosed
under the age of 60 years; (8) breast cancer, with two or
more relatives from the same side of the family diag-
nosed with breast cancer, where at least one family
member (either the patient or a relative) was diagnosed
under the age of 50 years; or (9) a proven BRCA1/2
mutation in the family. Women who meet one or more
of these criteria are considered to have a 10% or greater
chance of having a BRCA1/2 gene mutation [35,36].
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than 18 years of age, lack basic fluency in the Dutch
language, are incapable of understanding informed con-
sent, or are diagnosed with a breast cancer recurrence
or with metastastic disease. The patients are being
recruited from 12 hospitals in the Amsterdam and
Utrecht regions of the Netherlands.
Recruitment and randomization
Patient recruitment began in November 2008, follow-
ing approval by the ethical review committees of the
participating hospitals. Participating surgeons make use
of an 11-item checklist to determine patient eligibility.
All patients who meet the study inclusion criteria are
informed by the surgeon or nurse practitioner about the
study, and are given an envelope containing an informa-
tion letter, a consent form and the baseline question-
naire. Eligible patients receive a phone call by a member
of the research team within a few days, in order to carry
out the informed consent procedures and to administer
the baseline questionnaire to consenting patients.
Patients are then randomized to the RGCT or the UC
Participants complete 
baseline questionnaire 
No informed 
consent
Randomization 
Participants allocated
to UC (1/3) 
Participants allocated 
to RGCT (2/3) 
Follow-up (6 months) 
Follow-up (12 months)
Informed consent
Eligible patients receive information, 
consent form and baseline questionnaire
First consultation with 
clinical geneticist
Day 0: diagnosis
< 2 workdays after diagnosis
< 1 week after diagnosis
Figure 1 Study flow diagram.
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stratified per hospital and blocked per 9 cases [37].
These 12 random allocation sequences are generated by
an independent individual, are stored in computer files,
and remain unknown to the researchers until the patient
is randomized. The participant as well as the treating sur-
geon or nurse practitioner is informed about the randomi-
zation outcome. The researchers are blinded to
randomization outcome at the time of the baseline assess-
ments, but not at the follow-up assessments. This is due
to the fact that the researchers are responsible for arran-
ging appointments with the genetic counselor for those
women assigned to the RGCT arm of the study.
Intervention
Women in the RGCT group receive an appointment
with a clinical geneticist or genetic counselor within one
week following randomization, either at the Family
Cancer Clinic of the Netherlands Cancer Institute/
Antoni van Leeuwenhoek Hospital or at the Department
of Medical Genetics of the University Medical Centre
Utrecht. Those patients who decline to undergo RGCT
are given the opportunity to receive genetic counseling
and testing at a later time.
While the standard steps involved in genetic counsel-
ing are followed, the process is accelerated when
necessary. All patients are asked to complete a stan-
dard, detailed family history form in order to draw a
three-generation pedigree. Where possible, confirma-
tion of the (age at) diagnosis of the affected family
members is confirmed via medical record audits fol-
lowing required informed consent procedures. At the
time of the first consultation with the clinical geneti-
cist, the urgency of the steps to be taken are discussed
and a decision about DNA testing is made. If the
patient agrees, a blood sample for testing for mutations
in the BRCA1 and BRCA2 g e n e sc a nb et a k e no nt h e
same day. For women whose test result will not be of
immediate consequence for their choice of treatment,
the timing of the DNA testing does not need to be
accelerated (i.e., DNA test results will be made avail-
able within 4 months). Examples are women who,
from a medical point of view, cannot opt for breast
conserving therapy and have already had a contralat-
eral mastectomy, women who do not wish to take
immediate secondary preventive measures, or women
whose family history provides them with sufficient rea-
sons to undergo bilateral treatment regardless of
whether a mutation can be found.
Where it is anticipated that the DNA test results
could influence treatment decisions, a fast-track proce-
dure is used and the results are made available within
3 to 6 weeks. From a medical point of view, this timeframe
is sufficiently short to inform patients and clinicians about
the results before definite treatment decisions have to be
made.
The number of contacts between the patient and the
clinical geneticist prior to surgery depends on the com-
plexity of each individual case. For women who choose
not to undergo DNA testing, this may be limited to a
single session. For women who undergo DNA testing, at
least one additional session is held in order to discuss
the DNA test results. All results of the RGCT are for-
warded to the treating surgeon, and consultation
between the clinical geneticist and surgeon takes place
prior to and following the patient’s first appointment
with the clinical geneticist.
Psychosocial support is offered routinely to all women
who opt for rapid DNA testing, BRCA1/2 carriers and
to all women who are considering undergoing BLM
regardless of whether they have undergone DNA testing.
Where appropriate, referrals are made to mental health
caregivers in the hospital. The need for and uptake of
more intensive psychosocial care during subsequent
treatment are being assessed as part of the study.
Women in the UC condition receive standard advice
and care from their treating surgeon. In relation to the
possible hereditary nature of their disease, this typically
involves discussion of the family history and of appro-
priate surgical options. In some cases, patients may be
referred for genetic counseling or may self-refer. How-
ever, in current practice, this occurs rarely during the
pre-surgery period [38,39].
Study measures
Sociodemographic and clinical data
The patients’ age, education, marital status, ethnic back-
ground, work status and general health status are
obtained via the baseline questionnaire. Data on family
pedigree and genetic risk status are obtained via a ques-
tionnaire. Clinical data, including diagnosis, tumor char-
acteristics and treatment history (surgical treatment,
surgical complications, breast reconstruction, radiother-
apy, adjuvant chemotherapy or hormonal therapy) are
obtained via both questionnaire and medical record
audit. Results of the genetic counseling and testing,
including genetic test results, are obtained from the
records of the participating departments of clinical
genetics.
Choice of surgical procedure
The patients’ definitive surgical treatment decision is
determined via medical record audit. Via questionnaires
women are asked to report the factors motivating their
choice of treatment.
Risk perception is assessed with 4 items adapted from
previous studies [40-42] that inquire about current
perceived risk of recurrent or contralateral breast cancer
(all questionnaires), of ovarian cancer, and of the
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questionnaires). Women are asked to rate on a 5-point
scale how likely they think it is that they will develop
cancer again, and to rate their perceived risk on a con-
tinuous scale from 0% to 100%.
Cancer worries are assessed with 8 items, 6 of which
are adapted from previous work by Watson [40,43], that
measure the frequency of cancer-related worries, their
impact on mood, and their impact on daily functioning.
The Hospital Anxiety and Depression Scale (HADS)
[44] is used to assess psychological distress. The HADS
contains 14 items. Both a total score and separate scores
for anxiety and depression can be calculated. The HADS
has been validated for use in the Dutch population,
showing good psychometric properties, with Cronbach’s
alphas for both the anxiety and depression scales >0.70
[45-47].
Cancer-specific distress is assessed with the Impact of
Events Scale (IES), a 15-item Likert-scale organized
into 2 subscales: intrusive thoughts and feelings, and
avoidance of thoughts and feelings related to the
stressful situation. In this case, the stressful situation is
the diagnosis of breast cancer [48]. The IES has high
levels of internal consistency (alpha’s above 0.80) and
has been translated and validated for use in the Dutch
setting [49].
Satisfaction with decision-making is assessed with the
Satisfaction with Decision Scale (SWD) [50] and the
Decisional Conflict Scale [51,52]. The 6-item SWD-scale
can be adapted to any medical decision and, in this case,
refers to the choice of surgical treatment. The scale has
high internal consistency reliability (alpha = 0.86) [50].
The 16-item Decisional Conflict Scale contains three
subscales: ‘Uncertainty’, ‘Factors contributing’ and ‘Effec-
tive decision making’. The scale had high internal consis-
tency reliability (alpha of the three subscales ranges from
0.75-0.82 in the Dutch version).
Knowledge of breast cancer and its genetic aspects is
assessed with a 7-item, true-false-don’tk n o wq u e s t i o n -
naire adapted from Claes et al. [14,53].
Health-related quality of life is assessed with the
EORTC QLQ-C30 [54] and the EORTC breast cancer
module, the QLQ-BR23 [55]. The QLQ-C30 includes
5 functional scales, 3 symptom scales, and a number of
single item symptom measures. It is designed for use
with a broad range of cancer patient populations. The
QLQ-BR23 assesses breast cancer-specific symptoms,
treatment side-effects, body image, sexuality and future
perspective. Both questionnaires have been used exten-
sively in studies of women with breast cancer, and exhi-
bit good levels of reliability (alpha coefficients between
0.70 and 0.85) and construct validity.
Process-related variables
Perceived influence of the surgeon on treatment choice
is assessed with a series of questions adapted from
Schwartz et al. [24]. Women in the RGCT arm of the
study are asked a series of study-specific questions
about their experience and satisfaction with RGCT, and
their perceived need for additional psychosocial care.
Psychosocial care actually received is also being deter-
mined from the medical records and via self-report. The
content of the professional psychosocial support
received is also being assessed.
Sample size
The sample size calculations are based primarily on the
type of surgery chosen, and specifically on the uptake
of bilateral mastectomy. With a total sample of 255
women (170 in the RGCT arm and 85 in the UC arm),
the study will have 80% power to detect a difference of
18% versus 5% in the uptake of bilateral mastectomy,
w i t ht h ep - v a l u es e ta t0 . 0 5 .T h es a m p l es i z er a t i oo f
2:1 was chosen to ensure that the RGCT sample is
sufficiently large to obtain stable estimates of bilateral
mastectomy and delayed prophylactic contralateral
mastectomy uptake among BRCA1/2 carriers, and to
allow for secondary analyses (e.g., to examine predic-
tors of DNA testing uptake). The percentages indicated
above are based on the following assumptions: (1)
based on the participating hospitals’ experiences in the
previous three years, 5% of the women in the UC arm
are expected to choose bilateral mastectomy; (2) in the
RGCT arm, it is expected that 20% will test positive
for a BRCA1 or BRCA2 mutation, of whom, on aver-
age, 50% will opt for a bilateral mastectomy. Of the
remaining 80% of women in the RGCT arm, we expect
a 10% uptake of bilateral mastectomy. For the remain-
ing, primarily self-report outcomes (e.g., cancer worries
and cancer-specific distress, decisional satisfaction,
HRQL), the sample of 255 participants is more than
sufficient to detect a 0.5 standard deviation between-
group difference in mean scores. Based on data
obtained from the cancer registries of the Integral
Cancer Centers of Amsterdam and Middle Nether-
lands, and on data provided by the participating hospi-
tals, it is estimated that there will be a total of 2550
newly diagnosed breast cancer patients during the
recruitment period. Approximately 15% of these
women is expected to be eligible for participation.
Based on prior experience with recruitment of patients
into similar studies, we expect an 80% response rate.
This results in an expected N of 306 patients. This
allows for an attrition rate of 17%, while retaining 255
women for the primary analysis.
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Analyses will first be performed to evaluate the compar-
ability of the RGCT and the UC groups at study entry
in terms of sociodemographic and clinical characteris-
tics. Student’s t-test or appropriate non-parametric sta-
tistics will be used, depending on the level of
measurement. If the groups are not comparable on one
or more background variables, those variables will be
employed routinely as covariates in subsequent analyses.
Between group differences in choice of surgery will be
tested using the chi-square statistic or, if statistical
adjustment is required for covariates, multiple logistic
regression analysis. Analysis of (co)variance will be
employed to assess group differences at 6 and 12 month
follow-up in risk perception, psychological distress,
knowledge, decisional satisfaction, and HRQL. Where
appropriate, sociodemographic and clinical background
variables, as well as baseline scores on the outcomes of
interest, will be used as covariates. Effect sizes will be
calculated using standard statistical procedures. Supple-
mentary, descriptive analyses (both quantitative and
qualitative) will be used for reporting the patients’
experiences with RGCT. All primary analyses will, to as
great an extent as possible, be conducted on an inten-
tion-to-treat basis. That is, all women in the RGCT
group will be included in that group in the analyses,
regardless of whether they actually carried through with
RGCT. Supplementary analyses will be undertaken to
examine sociodemographic, clinical and psychosocial
factors associated significantly with (non-) attendance at
the RGCT and uptake of BLM.
Discussion
It is common practice to refer breast cancer patients
with suspected hereditary breast cancer for genetic
counseling and testing after their initial treatment has
been completed [38]. Women found to have a mutation
in the BRCA1 or BRCA2 gene may opt for additional
preventive surgery following their initial surgical treat-
ment. A complicating factor in delaying genetic counsel-
ing and testing until after the completion of primary
treatment is that, when that treatment includes radio-
therapy, additional, preventive surgical procedures
(e.g., mastectomy with breast reconstruction) may be
quite challenging for the plastic surgeon [33]. By offer-
ing genetic counseling and testing in the period between
breast cancer diagnosis and initial surgical treatment, it
is possible to incorporate the results of those procedures
into treatment decision-making. It is important to note
that genetic counseling, whether done prior to or fol-
lowing primary treatment, is non-directive in nature.
The intent is to provide women with information about
t h ep o s s i b l eh e r e d i t a r yb a s i so ft h e i rd i s e a s e ,s ot h a t
they can make informed choices regarding primary
surgical and adjuvant treatment, as well as possible pre-
ventive surgery. However, little information is currently
available on the benefits and potential problems asso-
ciated with RGCT from the patients’ perspective. It is
important to determine these effects now, as it is antici-
pated that RGCT will be increasingly common place, as
non-commercial genetic labs gear up to be able to gen-
erate DNA test results in only a matter of weeks. More-
over, rapid genetic counseling, in and of itself, may
influence treatment decisions. It should be noted that
the results of RGCT are not only expected to influence
the choice of surgical treatment, but may also have an
impact on chemotherapy options as well. Specific
chemotherapeutic agents such as PARP-inhibitors are
being developed that have antitumor activity in BRCA-
associated cancer [56].
Methodological considerations
The major methodological strength of this study is the
use a randomized controlled trial design which will
allow a rigorous test of the effects of RGCT with opti-
mal internal validity. The relatively large sample size
and the use of primarily standardized measures repre-
sent additional strengths of the study. Finally, the trial’s
multicenter nature should increase the external validity
or generalizability of the study findings.
A limitation of this study is the relatively short period
of follow-up (12 months). While this is sufficient for
examining the effect of RGCT on primary treatment
choice and on short term psychosocial outcomes, it
does not permit longer term follow-up on these latter
outcomes.
Conclusion
This study is expected to provide important information
on the impact of RGCT among newly diagnosed breast
cancer patients on the choice of surgical treatment and
on psychosocial well-being. Since RGCT is anticipated
to become common practice in the future, the results of
this study can contribute to improving the quality of
multidisciplinary breast cancer care.
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